Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).

Saved in:
Bibliographic Details
Title: Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
Authors: Battaglin F; USC Norris Cancer Center, Los Angeles, CA, United States., O'Neil BH; University Hospital Grosshadern, Munich, Germany., Stintzing S; Department of Hematology, Oncology, and Cancer Immunology (CCM); Charité - Universitaetsmedizin Berlin, Berlin, Germany; DKTK Heidelberg, Partner Site, Berlin, Germany. Electronic address: Sebastian.stintzing@charite.de., Ou FS; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States., Zemla TJ; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States., Niedzwiecki D; Department of Biostatistics and Bioinformatics and Duke Cancer Institute-Biostatistics, Duke University, Durham, NC, United States., Innocenti F; UNC Lineberger Cancer Center, Chapel Hill, NC, United States., Hochster HS; Yale Cancer Center, New Haven, CT, United States., von Weikersthal LF; MVZ Gesundheitszentrum St. Marien GmbH, Amberg, Germany., Decker T; Onkologie Ravensburg, Ravensburg, Germany., Kiani A; Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, Germany., Vehling-Kaiser U; VK&K Studienzentrum, Landshut, Germany., Heintges T; Department of Medicine II, Städtisches Klinikum, Neuss, Germany., Lerchenmüller C; Oncological Practice, Münster, Germany., Weiss L; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany., Heinrich K; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany., Goldberg RM; West Virginia University Cancer Institute, Morgantown, WV, United States., Mayer RJ; Dana Farber Cancer Center, Boston MA, United States., Schilsky RL; University of Chicago, Chicago IL, United States., Blanke CD; Oregon Health Sciences, Portland, OR, United States., Venook AP; UCSF Helen Diller Cancer Center, San Francisco, CA, United States., Lenz HJ; USC Norris Cancer Center, Los Angeles, CA, United States., Heinemann V; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Sep 09; Vol. 227, pp. 115694. Date of Electronic Publication: 2025 Aug 05.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115694